Oculis (www.oculis.com), a clinical-stage biotechnology company focused on the development of breakthrough non-invasive topical treatment for back-of-the-eye diseases, announced it has successfully closed a Series B financing round of CHF 20 million (USD 20.3 million). The financing was led by a syndicate of leading international life science investors including Bay City Capital, Novartis Venture Fund and Pivotal bioVenture Partners. Existing investors, including Brunnur Ventures and Silfurberg, also participated in the financing.
Prof. Stefansson, Oculis co-founder, was awarded Peter Watson prize and chair of Cambridge Ophthalmological symposium at the 47th Symposium of the Cambridge Eye Trust, held in St John’s College, Cambridge, UK from 6th – 8th September 2017. The topic of the symposium was “Go with the flow” rheology, fluid flow and the eye”.
Oculis ehf., announced today that a Eurostars application for the development of a novel eye-drop drug for the preventive treatment of diabetic retinopathy has been approved under the project name “PREVIN”.
Oculis’ scientists presented two inventions at this years ARVO Annual Meeting, held on May 7-11 in Baltimore, USA. The first presentation (Johannsdottir, et al;ARVO E-abstract 4442) reported on a preclinical study designed to develop a surfactant-free drop by delivering cyclosporin A via cyclodextrin nanoparticles. The eye-drop formulation with cyclodextrin nanoparticles exhibited no ocular irritation in […]
It was announced today that Oculis was one of two company’s awarded an honorary grant from the Icelandic Technology Development Fund. The Technology Development Fund’s role is to support research and development activities, which aim towards innovation in Icelandic industry. The Technology Development Fund is a competitive fund which issues its calls for proposals twice a year. The grant award is in the amount of ISK 70 million (USD 620 thousand) and is awarded towards the clinical development of Oculis lead candidate, DexNP.
Prof. Loftsson, Oculis’ co-founder, was awarded the AAPS Research Achievement Award in Physical Pharmacy and Biopharmaceutics at the 2016 AAPS Annual Meeting and Exposition held in Denver, USA from November 13-17. The award is granted for Prof. Loftsson’s research on cyclodextrins, including Oculis breakthrough SNP technology.
Dr. Einar Stefansson, Oculis’ co-founder, will make a presentation at Cambridge Healthtech Institute’s fourth annual Targeting Ocular Disorders conference. The conference takes place on September 21-22, 2016 in Boston, MA. Dr. Stefansson’s presentation, titled “Nanoparticle Eye-Drops Deliver Drugs to Retina in Human Patients” will discuss Oculis’ solubilizing nanoparticle (SNP) eye drop technology and is scheduled on September 20 at 3.15 PM under the section on innovative drug delivery methods for ocular disorders.
Oculis announced today the close of a Series A financing round, led by Brunnur Ventures and Silfurberg. The new capital will support continued development of the company’s patented solubilizing nanoparticle (SNP) drug delivery platform and the company’s drug candidates, including the first topical eye-drops for treatment of diabetic macular edema.
Prof. Einar Stefansson, Oculis’ chairman and co-founder, gave a honorary key note lecture at The Nordic Ophthalmology Congress in Denmark June 8-12, 2016 and received the biennial gold medal for his contribution to eye research. The lecture included Oculis’ break through nanotechnology that delivers drug molecules in eye drops to the back of the eye and offers noninvasive drug therapy for retinal diseases.
Prof. Thorsteinn Loftsson, Oculis’ co-founder and Chief Scientific Officer, is on the recently published Thomson Reuters’ list of The World’s Most Influential Scientific Minds for 2015. This is the second year in a row Prof. Loftsson is included on Thomas Reuters’ list of leading researchers.